Compare VERX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | BCRX |
|---|---|---|
| Founded | 1978 | 1986 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2020 | 1995 |
| Metric | VERX | BCRX |
|---|---|---|
| Price | $13.38 | $8.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $24.25 | $20.82 |
| AVG Volume (30 Days) | 1.2M | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $748,444,000.00 | $25,186,000.00 |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $11.61 | $12.55 |
| P/E Ratio | $302.25 | ★ N/A |
| Revenue Growth | ★ 12.25 | N/A |
| 52 Week Low | $10.59 | $6.00 |
| 52 Week High | $42.44 | $11.31 |
| Indicator | VERX | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 37.55 |
| Support Level | $11.38 | $7.94 |
| Resistance Level | $13.73 | $8.68 |
| Average True Range (ATR) | 0.79 | 0.46 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 38.07 | 23.34 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.